Physician
Michael G Valpiani MD Az LTD
Michael G Valpiani MD Az LTD was paid $2.35M by Medicaid between Jan 2018 and Dec 2024, across 31 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 77% of everything it billed.
33Billing provider infoMICHAEL G VALPIANI MD AZ LTD
KINGMAN, AZ 86409
KINGMAN, AZ 86409
33aNPI1902191992assigned 06/17/2011
33bProvider typeAnesthesiology Physician
28Total paid$2.35M
24GClaims61,094
24DCodes billed31
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Arizona
Rank by total paid#10 of 153
Median peer was paid$17K
This provider vs. median139×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,885 | $339K | |
| 2019 | 10,632 | $310K | |
| 2020 | 9,526 | $290K | |
| 2021 | 8,597 | $393K | |
| 2022 | 8,506 | $358K | |
| 2023 | 7,332 | $380K | |
| 2024incomplete | 5,616 | $279K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 77% | 35,544 | 30,748 | $1.82M |
| 96521 | 7.8% | 1,656 | 469 | $184K | |
| 99441 | 5.1% | 5,880 | 4,218 | $120K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.9% | 1,631 | 469 | $91K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.3% | 1,615 | 467 | $55K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.2% | 663 | 611 | $27K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 216 | 213 | $17K |
| 99493 | <1% | 137 | 122 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 289 | 271 | $8K |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 941 | 285 | $7K |
| 99492 | <1% | 41 | 41 | $4K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 67 | 67 | $4K |
19 more codes
| J1955 | Injection, levocarnitine, per 1 gm | <1% | 165 | $3K |
| 86328 | <1% | 40 | $1K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 196 | $103.71 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 25 | $83.29 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 113 | $32.83 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | <1% | 1,545 | $0.02 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 1,539 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 1,560 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 1,547 | $0.00 |
| G8539 | Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 1,605 | $0.00 |
| 1124F | 0% | 909 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 565 | $0.00 |
| 4004F | 0% | 95 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 212 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 759 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 467 | $0.00 |
| 1036F | 0% | 906 | $0.00 | |
| 1123F | 0% | 129 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVALPIANI, MICHAEL (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Michael Gene Valpiani MD LTD | Las Vegas, NV | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.